Today, the CSO of Myriad Genetics, Jerry Lanchbury, exercised options of Myriad Genetics (NASDAQ: MYGN) for $2.41M.
In addition to Jerry Lanchbury, 7 other MYGN executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
MYGN’s market cap is $2.81B and the company has a P/E ratio of 20.6. Currently, Myriad Genetics has an average volume of 512.3K.
10 different firms, including Merrill Lynch and Citigroup, currently also have a Sell rating on the stock. Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $38.00, reflecting a 4.0% upside.
The insider sentiment on Myriad Genetics has been negative according to 50 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Jerry Lanchbury’s trades have generated a 8.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.
